Tax Season is Here! Save 15% on H&R Block Online
iconAll times are GMT -4. The time now is 07:17 PM. | Search:

» StockRants Stock Forum » Public Stock Forums » US Stock Picks » Strong Buy: ARDX (MC $155 M) FDA Decision on Sept 12 & Phase 3 readout this Quarter



Reply
 
Thread Tools Search this Thread
Old 08-19-2019, 08:04 AM   Nav to Top  #1
Biohero
Senior Trader
 
Biohero's Avatar
 
Join Date: Jan 2012
Location: Frankfurt
Posts: 239
Favorites: Aapl celg onxx
Rep Power: 104
Reputation: 36
Biohero is on a distinguished road
Default ARDX (MC $155 M) FDA Decision on Sept 12 & Phase 3 readout this Quarter

FDA Decision for IBS-C Drug (irritable bowel syndrome with constipation) on September 12, 2019 and Phase 3 readout of the AMPLIFY clinical trial for the treatment of Hyperphosphatemia also in Q3 2019 . Tenapanor has over $500 million commercial opportunity in each of these indications. ARDX almost trading at cash level which shows how significantly underpriced this company is .


Ardelyx (ARDX)

Market-Cap : $155 million
Cash: $124 Million
Price: $2.47


Remaining Expected 2019 Milestones

The company's New Drug Application for U.S. marketing authorization of tenapanor for patients with IBS-C has a target action date under the Prescription Drug User Fee Act (PDUFA) of September 12, 2019.

Results from the AMPLIFY clinical trial, the company's Phase 3 clinical trial evaluating tenapanor's efficacy in combination with phosphate binders, are currently expected to be announced in the third quarter of 2019.

Results from the PHREEDOM clinical trial, the company's second Phase 3 clinical trial evaluating tenapanor as a monotherapy treatment for hyperphosphatemia in patients with end-stage renal disease (ESRD) who are on dialysis, are currently expected to be announced in the fourth quarter of 2019.

5 Biggest New Drug Approvals Potentially on the Way in 2019....August 19, 2019
https://finance.yahoo.com/news/5-big...100000979.html

5. Tenapanor

Small biotech Ardelyx should be only a few weeks away from some big news. The FDA is scheduled to announce an approval decision for tenapanor in treating irritable bowel syndrome with constipation (IBS-C) by Sept. 12, 2019.

EvaluatePharma expects that the drug could pull in nearly $700 million annually by 2024 if it's approved. Ardelyx hopes that the IBS-C is only the first of two approved indications for tenapanor. The company is also evaluating the drug in a phase 3 clinical study for treating hyperphosphatemia in patients with end-stage renal disease (ESRD) who are on dialysis.
Big impacts

FDA approvals for lumateperone and tenapanor would definitely have huge impacts for Intra-Cellular Therapies and Ardelyx. Neither company has an approved product on the market yet.


Ardelyx transported by success in IBS-C; tenapanor exchanges suffering for relief
Ardelyx transported by success in IBS-C; tenapanor exchanges suffering for relief | BioWorld


Ardelyx Announces Peer-Reviewed Publication of Positive Phase 3 Results of Tenapanor for the Treatment of Hyperphosphatemia in the Journal of the American Society of Nephrology
https://www.prnewswire.com/news-rele...300808726.html


Biohero is offline   Rate this post Yes | No Reply With Quote
Old 08-19-2019, 10:20 AM   Nav to Top  #2
Biohero
Senior Trader
 
Biohero's Avatar
 
Join Date: Jan 2012
Location: Frankfurt
Posts: 239
Favorites: Aapl celg onxx
Rep Power: 104
Reputation: 36
Biohero is on a distinguished road
Thread Starter
Default

Could hit $4-5 before FDA decision in 3 Weeks ....

Biohero is offline   Rate this post Yes | No Reply With Quote
Old 09-03-2019, 01:22 PM   Nav to Top  #3
Biohero
Senior Trader
 
Biohero's Avatar
 
Join Date: Jan 2012
Location: Frankfurt
Posts: 239
Favorites: Aapl celg onxx
Rep Power: 104
Reputation: 36
Biohero is on a distinguished road
Thread Starter
Default

positive phase 3 results out today ,,, next is FDA decision on Sept 12 = $10++ stock here
...LOVE IT
https://finance.yahoo.com/news/ardel...120000881.html
Biohero is offline   Rate this post Yes | No Reply With Quote
Reply

Similar Threads
Thread Thread Starter Forum Replies Last Post
Nasdaq Composite - Technical Analysis - Sept 25, 2012 mudgalbharat Trend Spotting 5 07-02-2014 10:39 AM
Watch: NOK - Awaiting Sept 5th cristianogirardelli US Stock Picks 0 09-03-2012 05:29 AM
Another 2nd Rate Decision dodjit Traders Lounge 0 09-10-2009 03:29 AM


Thread Tools Search this Thread
Search this Thread:

Advanced Search

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is On